Fred Telling sold $12k of OGEN
director at ORAGENICS INC. 3,500 shares at an average of $3.57, traded Nov 30, 2023, filed Dec 1, 2023.
Score components
- +15RoleDirector
- 0Trade size$12k at market
- 0Share of holdings soldSold 8.4% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +62.7%, 3m -58.7%, 6m -41.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-23-043456, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 30, 2023 | SOpen-market sale Common Stock | -3,500 | $3.57 | $12k | 38,345 | Dec 1, 2023 |
Related signals
Other insiders at ORAGENICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | OGENsell ORAGENICS INC | Fred Telling director | $198 210 shares | -18% | |
| 15Weak | OGENsell ORAGENICS INC | Fred Telling director | $198 210 shares | -1% | |
| 37Weak | OGENsell ORAGENICS INC | Odyssey Health, Inc. owner | $30k 7,044 shares | -100% | |
| 38Weak | OGENsell ORAGENICS INC | Odyssey Health, Inc. owner | $44k 10,000 shares | -59% | |
| 23Weak | ORAGENICS INC | Alan W Dunton director | $24 66 shares | -0% | |
| 23Weak | ORAGENICS INC | Fred Telling director | $1,295 3,597 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.